RECURSION PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Recursion Pharmaceuticals, Inc. released an updated investor presentation. The investor presentation will be used at the JP Morgan Healthcare meeting and from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 7.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.       Description

99.1                Investor presentation of Recursion Pharmaceuticals, Inc. dated
                  January 10, 2022.

104               Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses